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THE NEWEST SCOURGE
From the Bowels of an Epidemic: AIDS,
Human Rights and International Equity
Ronald Bayer
I. Introduction
Epidemic diseases, we know, can be the source of profound disrup-
tion. In addition to the death and suffering they bring, they can serve
as the occasion for great social conflict. Not unusually, those who have
been socially marginal in a pre-epidemic era have become the targets
of attack, depicted as the source of disease in the face of the threat
posed by the outbreak of illness: Jews in medieval Europe, Asian and
other immigrants to America in the 20th century, and, in the context of
AIDS, gay men. But epidemic diseases, precisely because they so
starkly reveal social fault lines and institutional inadequacies, can pro-
vide the occasion for progressive changes and ideas designed to
address the limits of the pre-epidemic order.
I turn to the grave AIDS epidemic, which threatens the lives of mil-
lions of men, women, and children globally, and I examine the way in
which a disease threat that first emerged on the world stage in 1981
has served to force a rethinking about the ethics of disease prevention,
the conduct of research involving human subjects, the limits of the
market, and moral obligations beyond our borders. In each instance, I
will turn first to how the issue was addressed in the United States and
other wealthy nations and then to how the impact of AIDS in the poor-
est nations has forced more radical rethinkings.
II. The Two Worlds of AIDS
There was a time in the early days of the AIDS epidemic when a grim
global equality defined the experience of all nations. In the richest
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countries and in the poorest, medicine was all but impotent to meet the
challenges of a disease that struck in the prime of life, and that ren-
dered physicians helpless as their patients quickly succumbed to a suc-
cession of opportunistic diseases. In the industrialized nations, the
onslaught was especially unsettling because in the post-antibiotic era,
epidemics of infectious disease had all but been consigned to history.
In the less developed nations, where the pattern of morbidity and mor-
tality still reflected the impact of infectious diseases, AIDS threatened
to reverse the hard won successes of public health, robbing years from
life expectancy.
What made for a common pattern of misery in the epidemic’s early
years were the limits imposed by our shared medical ignorance.
Slowly, however, that common bond began to yield to the developing
understanding of how HIV rendered the immune system helpless, and
a growing understanding of how to treat and even prevent the oppor-
tunistic diseases that took the lives of those who were infected. And at
that juncture, the global inequalities that made infectious diseases
treatable in the richest nations but untreatable in the poorest began to
affect the experience of a common pathogenic threat. No longer did the
limits of medicine define the situation. Rather, it was the inability to
afford treatments because of resources. Just as diarrheal diseases were
preventable and treatable when they occurred in wealthy nations but
ravaged communities in the poorest nations, and just as tuberculosis
was preventable and treatable when it occurred in the richest nations
but took the lives of millions in the less developed nations, opportunis-
tic diseases linked to HIV began to yield to successful treatments in the
industrialized nations while they continued to take their toll in the
poorest.
But the therapeutic and prophylactic advances that began to trans-
form the world of AIDS in terms of opportunistic diseases was not so
quick to affect experience with regard to the underlying threat caused
by HIV itself. Men, women, and children across the economic divide
continued to die in large numbers, albeit sooner in the poorest coun-
tries than in rich nations.
Hopes for assaulting HIV infection itself with antiretroviral drugs
were repeatedly shattered. Research findings that suggested that AZT,
the first antiretroviral, would radically improve life expectancy for
those with the fully developed disease and even slow the onset of dis-
ease in asymptomatic HIV infected individuals were, all too soon,
shown to be illusory.
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But then in 1994, things began to change. With those changes came,
once again, the roots of an inequality born of medical and scientific
progress. First, there was the remarkable discovery in a clinical trial
that AZT administered during pregnancy could reduce the rate of
maternal-fetal transmission by two-thirds. A first antiviral success
promised to make pediatric AIDS an increasingly uncommon tragedy,
at least for those who could afford the cost of treatment. Then, in 1995–
1996, even more remarkable discoveries about the power of combina-
tion therapies involving multiple retrovirals provided the basis for
thinking that AIDS could be transformed from a rapidly fatal disease
into a chronic illness, which, if still ultimately fatal, would no longer be
marked by death so soon after diagnosis (at least in those countries
that could afford the extraordinarily costly treatments).
Thus has the advance of science and medicine brought to an abrupt
end the era of grim global equality. Two worlds of AIDS have there-
fore emerged—one where AIDS is treatable and those infected can live
for years under careful, costly medical management, and another
where AIDS equals death.
Let me now fill in this picture, turning to two sets of data that will
underscore how different the worlds of AIDS have become. The first is
based on the perspective of American physicians revealed in long in-
depth interviews that are included in the recent book AIDS Doctors:
Voices from the Epidemic, which I wrote with Gerald Oppenheimer. The
second is drawn from a report published by the United Nations.
The encounter with AIDS in the early 1980s compelled many of the
first AIDS doctors in America to rethink their therapeutic optimism
and the assumptions that dominated the curative orientation, which
reflected the achievements of medicine in economically advanced
nations. Gerald Friedland, who treated impoverished drug users in
New York, like others, needed to rethink the goals of medicine. Only
such a transformation could permit him to endure the work to which
he had committed himself.
I had lived in Nigeria for two years. It really helped me to know what
the limits of medicine are. I never had the delusion that we were going to
conquer this thing. It’s the wrong thing to talk about. As long as we keep
talking about cure, we’ll always feel like failures. We’re not failures.
What do we cure? So we’re limited, I’ve always felt limited as a physi-
cian.
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In a nation where infants and children almost never fell victim to fatal
disease, it was startling to encounter dying children, even among the
poorest. Trained in El Salvador, Hermann Mendez was forced to
remember his early medical experiences as he treated dying infants in
Brooklyn, New York.
I became used to death (at home) I mean, from the autopsy room to the
emergency room where we would receive very, very sick children all the
time. I got re-educated in the United States. I came fresh, full of desire to
practice differently, with a different population, and I allowed myself to
be re-educated, so my losses were hard losses.
For virtually all doctors, it became all too apparent that only if they
came to accept death as the inevitable fate of their AIDS patients could
they provide the kind of care that was clinically relevant, that met their
patient’s needs. Constance Wofsy of San Francisco thus noted:
How long it took before it eventually became clear that we have to
accept death in young people as something that did happen. We were
moving from how we were going to resolve this? to how we can make
this least painful, relieve suffering and achieve the longest, best life span
possible? It will sound macabre, but I realized I was travel agent for
death and that my role was to make the process as drawn out, as com-
fortable, and as full of interesting things as it was possible to do. I could
not prevent the ultimate outcome but I could manage it.
Others expressed a despair that merged with disdain as they con-
sidered the undue optimism that informed the work of researchers
whose careers were built on conducting expensive, but what they took
to be futile, efforts to discover powerful antiretroviral agents. Donald
Kotler remarked:
What it takes to not be a stupid fool is to accept the fact the first time you
see the patient that the patient will die of the disease. I’ve helped a lot of
people. I haven’t cured anyone. The people who made their careers
doing Phase 1 trials of one new antiretroviral after another have done
very well for themselves but in some ways haven’t done anything for
their patients.
In sum, the first generation of AIDS doctors in America sought to
reframe their understanding of what it meant to be a physician under
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conditions that many equated to a kind of grim trench warfare. Many,
overwhelmed by the experience, found themselves depleted and
exhausted. So accustomed had they become to death and therapeutic
limits that when the first good news of the mid-1990s presented itself,
they responded with profound skepticism. Was this to be another
AZT-like cycle of inflated premature hopes to be followed by shattered
expectations? But as clinical experience began to reveal how truly
remarkable the new combination therapies were, doctors began to rec-
ognize how radical a transformation was occurring. Richard Chaisson,
whose clinic in Baltimore, Maryland, treated poor African Americans,
had been skeptical in 1996. By 1998, his perspective had changed:
My initial response was more pessimistic than the events of the last two
years would warrant. The new drugs are extraordinary. However, they
are not having the effect of curing people; and so ultimately the question
is how long will this last. But the fact that people who were months
away from dying are robust and healthy and enjoying life now two,
three years afterwards is wonderful. I haven’t had a patient die for 10 or
11 months. So it’s gone from constant death to infrequent death. Mortal-
ity in our clinic in the last three years has fallen by about 65 percent.
Wafaa El-Sadr, at Harlem Hospital in New York, had a similar experi-
ence:
I would walk into clinic several years ago and just look at the waiting
room to see who’s there. And there were a lot of sick people, leaning
against the wall, very sick people. And now it’s just amazing. I walk in,
and it’s like bubbling with energy and conversation, people hanging
outside the door, smoking cigarettes; it’s just filled with life and energy, I
think it’s wonderful. When I see a sick person today at that clinic it’s
unusual. The very sick people are in the hospital. It’s almost like having
a well-baby clinic.
Barbara Starrett, a physician who had treated gay men and who in des-
peration had been willing to provide access to many alternative thera-
pies, captured the new optimism of many:
I think probably everybody that I take care of now is going to live for
years. They all have the potential to die of something else. Like hyper-
tension in the 50s. Many of those people on those imperfect drugs did
live complete lives. So now we’re going to have patients who live com-
plete lives on these AIDS drugs.
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Even those like Dan William, a longtime AIDS doctor in New York,
who were more cautious, saw what they took to be a transformation of
seismic implications:
I think we’re entering into the disease as chronic illness rather than a ter-
minal disease. That’s my prediction. I think it’s quite likely that AIDS
wards are going to be emptying out, not unlike iron lung wards in the
fifties, that people are going to be doing better, and they won’t need to
be in the hospital as much, and there will be fewer AIDS associated
opportunistic infections.
Writing of the changes at the end of 1998, the New England Journal of
Medicine captured epidemiologically what clinicians were seeing
among their patients:
The good news continues in the battle against AIDS. In the United
States, the age-adjusted death rate among young people with human
immunodeficiency virus (HIV) in 1997 was less than 40 percent of what
it was in 1995. The 16,685 deaths in 1997 represent the lowest annual
total in nearly a decade. . . . Not only has mortality from AIDS decreased,
but so has the incidence of AIDS among those who have HIV infec-
tion. . . . The dramatic declines in morbidity and mortality due to AIDS in
Western nations are the result of the widespread use of potent combina-
tions of antiretroviral drugs.
As the number of AIDS-related deaths declined, and as the deaths
became less frequent, American doctors began to find that the hard
won insights about how to practice medicine that emerged during the
bleakest years began to lose their compelling force. No longer was car-
ing as contrasted with curing viewed as a central mission of medicine.
With new therapeutic tools, it was possible for the conventions of cura-
tive medicine, so denigrated in the epidemic’s first years, to reassert
themselves. Doctors began to see themselves as, once again, becoming
real doctors, sometimes with a bittersweet nostalgia for the past. The
observations of Gerald Friedland, who had in the early years com-
forted himself with the idea that doctors could not cure, were thus
striking:
It’s really been wonderful, so much so that it’s almost hard to remember
what it was like when everybody was dying. It’s a magical moment. I
reminisce about the good old days when you couldn’t do anything. Isn’t
Macalester International Vol. 11
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that terrible? Because you had to focus on the caring part, and the love
and interaction and the arrangements of a good death. Now we’re more
like doctors. We write prescriptions all the time; we wind up juggling
medicines. With so much involved in the technical aspects of care that
you don’t have time for some of the human things; and so it has
changed. On the scale of things, it’s much better. People live longer, their
quality of life is better, but something has been lost in the increasing
complexity of AIDS care.
In the face of these dramatic events, a number of AIDS doctors
began to describe changes that would have been unthinkable just a few
years earlier. After years of devotion forged in the face of death and
therapeutic limits, some began to speak of disengaging from the sin-
gle-minded commitment to AIDS patient care. “It’s not like war any-
more,” said one.
Donald Abrams in San Francisco, who had seen thousands of
patients die, and who, like other gay physicians, had witnessed the
death of countless friends, and lovers as well, captured the mood of
some:
We were pioneers and were involved in a strange new frightening, chal-
lenging problem-solving endeavor. And it is now a bit like cancer in that
research is sort of looking at three drugs compared to those four and
which one gives you the marginal improvement in the surrogate marker
benefit. You are not dealing with the intensities that we were dealing
with previously, which were fear, contagion, death and disfigurement.
A lot of the drama and the intensity of the early days of the epidemic are
gone. Now you go to these AIDS conferences and there are just millions
and hundreds of people doing what we used to do or what we do. I have
worked in this now for 18 years and I probably have another 18 years left
in my career. I would really prefer being on the front lines again doing
something that is unique.
That, then, is the world of AIDS in America, where 40,000 people a
year continue to become infected with HIV, where people continue to
die of AIDS. But the carnage of the early years has ended. It is not too
different in other wealthy nations. But very different is the picture in
the poorest nations, those in Africa especially.
What is that other world of AIDS? In a careful analysis of both the
epidemiological and clinical picture that makes the account of death
and suffering all the more brutal, we are told by UNAIDS, the interna-
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tional agency that seeks to coordinate AIDS efforts, that there are 24.5
million HIV infections in sub-Saharan Africa; 5.6 million in South and
Southeast Asia; and 1.3 million in Latin America. Globally, 34 million
are infected. In 1999, 4.7 million adults and 600,000 children younger
than 15 were newly infected. There were 2.8 million deaths, 500,000
among children.
In an analysis based on modeling, UNAIDS has projected that any
country where 15 percent or more of adults are currently infected with
HIV, at least 35 percent of boys now aged 15 will die of AIDS — num-
bers that are both numbing and appalling. And the number of those
infected has long exceeded 15 percent in some nations. In South Africa,
Zambia, and Botswana, the deaths may exceed 60 percent unless radi-
cal changes in the incidence of infection occur or change in therapeutic
options become possible. The notion of a plague, like the great Bubonic
plague of the European Middle Ages, is no longer a metaphor. It is real
and it is harsh.
It is against this backdrop that we are compelled to: rethink the
value choices involved in preventing HIV transmission — a rethinking
that entails a reconsideration of the relationship between public health
and individual and human rights; reconceptualize the ethical chal-
lenges of conducting research with human subjects, especially con-
cerning a disease characterized by profound social inequalities; and
finally confront the question of the rights of the poorest in the world to
have access to treatments available to those who live in the wealthiest
nations.
III. Rights and AIDS Prevention: Toward a New Paradigm?
In the early and mid-1980s, when democratic nations were forced to
confront the public health challenge posed by the AIDS epidemic, it
was necessary to face a set of fundamental questions. Did the history
of responses to lethal infectious diseases provide lessons about how
best to contain the spread of HIV infection? Should the policies devel-
oped to control sexually transmitted diseases or other communicable
conditions be applied to AIDS? If AIDS were not to be so treated, what
would justify such differential policies?
To understand the importance of these questions, it is necessary to
recall that conventional approaches to public health threats were typi-
cally codified in the latter part of the 19th and early part of the 20th
century. Even when public health laws were revised in subsequent
Macalester International Vol. 11
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decades, they tended to reflect the imprint of their genesis. They pro-
vided a warrant for mandating compulsory examination and screen-
ing, breaching the confidentiality of the clinical relationship by
reporting to public health registries the names of those with diagnoses
of “dangerous diseases,” imposing treatment, and, in the most extreme
cases, confining persons through the power of quarantine.
As the century progressed, the most coercive elements of this tradi-
tion were rarely brought to bear, because of changing patterns of mor-
bidity and mortality and the development of effective clinical
alternatives. Nevertheless, it was the specter of these elements that
most concerned proponents of civil liberties and advocates of gay
rights as they considered the potential direction of public health policy
in the presence of AIDS. Would there be widespread compulsory test-
ing? Would the names of the infected be recorded in central registries?
Would such registries be used to restrict those with HIV infection?
Would the power of quarantine be used, if not against all infected per-
sons, then at least against those whose behavior could result in the fur-
ther transmission of infection?
Although there were public health traditionalists in the United
States and abroad who pressed to have AIDS and HIV infection
brought under the broad statutory provisions established to control
the spread of sexually transmitted and other communicable diseases,
they were in the distinct minority. Often such opponents viewed the
antagonism to traditional public health measures as a political distor-
tion. One such critic in the United States wrote, “Plagues are not new,
what is new are efforts by medically unsophisticated politicians and
attorneys to dictate policy . . . AIDS isn’t a civil rights issue. It’s a gen-
uine plague.” Typically, it was those identified with conservative polit-
ical parties or movements who endorsed such efforts — although not
all conservatives pursued such a course. Liberals and those identified
with the democratic left tended to oppose such measures. There were
striking exceptions, such as the Swedish Social Democrats, but in the
end, it was those who called for “HIV exceptionalism” who came to
dominate public discourse.
In the first decade of the AIDS epidemic, an alliance of gay leaders,
civil libertarians, physicians, and public health officials began to shape
a policy for dealing with AIDS that reflected the exceptionalist per-
spective. What accounted for the commitment to the exceptionalist
idea that there was no true conflict between civil liberties and the pub-
lic health, that the protection of the rights of the infected against
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unwarranted discrimination was central to the task of AIDS preven-
tion, and that persuasion and voluntarism were the core principles that
should animate the public health response to the new challenge?
First, AIDS was not a threat like, for example, tuberculosis. Because
it was transmitted largely in the context of acts between consenting
adults in private, a behaviorally informed response was crucial, one
that sought to understand why people acted in ways that placed them-
selves at risk, and that sought to craft interventions that could moti-
vate behavioral change. Only the most intrusive forms of surveillance
and the most drastic invasions of privacy could even theoretically
serve the ends of prevention in lieu of efforts at persuasion. From an
ethical perspective, the nature of HIV transmission dictated a new
public health approach. “The disease’s mode of contagion,” said
Richard Mohr, a philosopher, “assures that those at risk are those
whose actions contribute to their risk of infection. . . . It is the general
feature of such exposure that makes direct governmental coercive
efforts to abate the disease particularly inappropriate.”
Second, AIDS in the first epidemic years was seen largely as a dis-
ease of gay men. For those who had struggled against homophobia
and the threats of a government that had criminalized their sexual
lives, the prospect that AIDS would serve as a justification for the abro-
gation of privacy rights was anathema, and they used extraordinary
political skill in pressing their case. At times the case was pressed
through the conventional methods of constituency politics, at times
with forceful advocacy, and on occasion demonstrative protests were
crucial.
Third, those most affected by the epidemic, gay men and drug
users, viewed the state as a threatening entity. Any measure that might
further serve to alienate them and drive a wedge between public
health officials and those with whom it was critical to establish rela-
tionships of cooperation was thought to be counterproductive. In the
words of Surgeon General C. Everett Koop, coercive measures would
“drive the epidemic underground.”
Finally, in the absence of clinical interventions that could alter the
course of disease in those who were infected or that could reduce their
infectiousness, many of the conventional approaches to public health
that were predicated on the efficacy of identifying the infected were
simply irrelevant.
As the contours of the exceptionalist perspective were taking form,
some saw the emergence of a new way of thinking about public health,
Macalester International Vol. 11
210
one that eschewed the authoritarianism of an earlier era. The lessons of
AIDS would, it was thought, be applied in the face of other threats to
communal well-being. AIDS would have thus served to provide the
foundation of a new public health. But such optimism ultimately con-
fronted a series of changes that undermined the foundations of excep-
tionalism in the United States and in other democratic nations as well.
Epidemiological changes began to transform the face of AIDS. From
the late 1980s onward, the proportion of new infections associated
with intravenous drug use increased, as did the proportion of those
with HIV who were African-American and Latino. These transforma-
tions affected the extent to which white middle class men were inter-
ested in and could influence the course of public health prevention
policy. Secondly, public health officials with years of experience began
to consider the relevance of their own traditions of epidemic control.
But most importantly, the transition from near therapeutic impotence
to the era of effective clinical management of HIV disease has pro-
foundly affected the understanding of how traditional public health
approaches to screening could be brought to bear in the face of AIDS.
And so we have witnessed efforts to return AIDS to the clinical and
public health mainstream. The era of HIV exceptionalism is drawing to
a close. But lessons about the relationship between the protection of
individual rights and public health have not been lost. They have
become part of a new convention. Most significantly, there is a deeper
appreciation of how restrictive measures, to the extent that they are
ever needed, should be thought of as a last resort rather than as the
first line of defense.
It is not surprising that the exceptionalist perspective that so
informed policy in the advanced industrial nations, and especially the
United States, would influence and shape the response of the World
Health Organization (WHO) as it began to confront AIDS in the mid-
1980s. It was in that context that the issues were framed in terms of
human rights and within which a paradigmatic transformation
occurred, propelled by the unique sense of vision, the almost mission-
ary zeal of Jonathan Mann, who directed the WHO’s AIDS efforts in its
formative period.
In its first stage, the human rights-informed response to AIDS
focused on the necessity of protecting people with HIV infection from
discrimination in public life, and asserted the importance of privacy
protections and the right to be free from compulsory measures. While
human rights treaties always recognized that serious threats to the
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public health could justify restrictions on some rights, the new per-
spective tended to minimize the extent to which rights and welfare
might be in tension. “Public health interests do not conflict with
human rights. On the contrary, it has been recognized that when
human rights are protected, fewer people become infected and those
living with HIV/AIDS and their families can better cope.”
Most noteworthy was the way in which such a formulation instru-
mentally justified the centrality of human rights. It was not that human
rights were of such importance that some risks to the communal health
should be tolerated rather than endure rights-limiting interventions.
Rather, rights-limiting interventions threatened the communal health.
The AIDS policies of the Cuban government were the specter that
haunted this worldview. In that country, a decision had been made to
apply the practice of compulsory screening to the entire adult popula-
tion and to place in quarantine all those found to be infected. To the
extent that such an approach worked effectively to reduce the rate of
HIV transmission, it would compel an analysis of the way in which
respect for individual rights and public health were, in fact, in tension.
In the end, the Cuban example was simply denounced as involving a
gross violation of human rights, which would eventually prove to be a
failure from the perspective of public health.
While there was broad international consensus on the relationship
between human rights and AIDS prevention, Jonathan Mann pressed
the most uncompromising posture in the years after he left the World
Health Organization. Writing from the vantage point as director of a
human rights center at Harvard University in the journal Health and
Human Rights (which he founded and edited), Mann declared, “All
public health policies and programs should be considered discrimina-
tory (or otherwise burdensome on rights) until proven otherwise.”
Mann, to be sure, understood that such a formulation was provocative,
but it was a necessary provocation if rights were to be taken seriously.
More far-reaching than the link between health and civil and politi-
cal rights — the individual rights of liberal democracy — was Mann’s
encounter with the question of how social inequality affected the vul-
nerability to disease. Targeting the analyses that alluded to the risk fac-
tors of individuals he wrote:
This view of disease as external, invading societies which would pre-
sumably otherwise enjoy good health, frames a problem such as cancer
in the following terms: we have a cancer problem; what can we do about
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it, within the given social system? Inevitably this framing and definition
of the problem leads to a focus on individual behavior. Individual
behavior is implicitly assumed to be largely a matter of choice.
The social conditions shaping the pattern of disease thus remained
unaddressed. Such an approach, argued Mann, would have major ben-
efits for a few, “some benefit for some, and little benefit to many or
most.” By contrast, his new focus was on a social analysis that led to
social action:
The new public health recognizes that the positive impact of traditional
public health work will be inherently limited and inadequate without a
commitment to changing societal conditions which constrain health and
create vulnerability to prevent disease, disability and premature death.
The encounter with AIDS and the limits of the liberal conception of
human rights had led Mann to forge a contemporary movement
focused on the social roots of vulnerability: poverty, inequality, and
marginalization. In so doing he had, without explicitly acknowledging
those who came before him, joined the tradition that stretched back 
to Engels’ Condition of the Working Class in England, Virchow’s analyses
of diseases and the social structure in the 19th century, and Thomas
McKeown’s work in the 20th century. In short, he had rediscovered a
social medicine. There was in this radical outlook a profoundly sober-
ing warning: the meliorist efforts designed to limit the spread of HIV
were all but useless. Only if the root causes of vulnerability were
addressed could the epidemic’s toll be limited.
How Mann’s ideas might have evolved will never be known. His
life was tragically cut short in an airplane crash a little more than two
years ago. But his ideas have been instrumental in forging a broad con-
stituency linking health and human rights, a movement that has
sought to repackage the venerable ideas of social democracy in terms
perhaps more palatable to a 21st century dominated by the hegemony
of free market ideology.
As Mann and others focused on the challenges of prevention, others
turned to issues of how best to conduct research to find therapeutic
interventions that could have an impact on the life prospects of those
who were already infected, research that would at the same time
adhere to basic principles of ethics.
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IV. Engaging the Ethics of Human Experimentation
The contemporary history of human experimentation is haunted by
the specter of abuse. The work of the Nazi doctors exposed at Nurem-
berg, the Tuskegee syphilis study that exploited poor black men in the
American South, and the catalogue of misdeeds made public by Henry
Knowles Beecher in the New England Journal of Medicine all provide the
backdrop to the effort to formulate ethical standards to guide the con-
duct of investigators who are dependent on the collaboration of
women, men, and children as they seek to advance the scientific
understanding of disease and its cures.
In the mid-1970s, the U.S. National Commission for the Protection
of Human Subjects of Biomedical and Behavioral Research examined
these issues and in its Belmont Report codified a set of ethical principles
that sought to inform the work of researchers. Those norms provided
the foundation for regulations subsequently enacted by the Depart-
ment of Health and Human Services and the Food and Drug Adminis-
tration. At the core of those guidelines was the principle of informed
consent and the radical distinction between research designed to pro-
duce socially necessary, generalizable knowledge, and therapy
designed to benefit individuals. Against the former, individuals, espe-
cially those who were socially vulnerable, needed protection against
conscription.
AIDS forced a reconsideration of this formulation in the United
States. There had been challenges to federal protections in the past, for
example when prisoners at Jackson State Prison in Michigan
demanded that they be permitted to serve as research subjects because
participation provided them with social advantages. But the HIV epi-
demic provided the circumstances for the emergence of a broad and
potent political movement that sought to radically reshape the condi-
tions under which research was undertaken. The role of the random-
ized clinical trial, the importance of placebo controls, the centrality of
academic research institutions, the dominance of scientists over sub-
jects, the sharp distinction between research and therapy, and the pro-
tectionist ethos of the Belmont Report were all brought into question.
Scholars concerned with the methodological demands of sound
research and ethicists committed to the protection of research subjects
played a crucial role in the ensuing discussions, both as defenders of
the received wisdom and as critics, but the debate was driven by the
articulate demands of those most threatened by AIDS. Most prominent
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were groups such as the People with AIDS Coalition and ACT-UP,
organizations made up primarily of white, gay men. But advocates of
women’s, children’s, and prisoners’ rights also made their voices
heard. What was stunning and disconcerting to some but exciting to
others was the rhythm of challenge and response. Rather than the care-
ful exchange of academic arguments, the mobilization of disruptive
and effective political protest forced the process to change.
The threat of death hovered over the process. As Carol Levine noted
in her essay, “Has AIDS Changed the Ethics of Human Subjects
Research?:”
The shortage of proven therapeutic alternatives for AIDS and the belief
that trials are, in and of themselves, beneficial have led to the claim that
people have a right to be research subjects. This is the exact opposite of
the tradition starting with Nuremberg that people have a right not to be
research subjects.
That striking reversal resulted in a rejection of the model of research
conducted at remote academic centers, with restrictive (protective)
standards of access, and strict adherence to the “gold standard” of the
randomized clinical trial. Blurring the distinction between research
and treatment — “A Drug Trial is Health Care Too” — those insistent
on radical reform sought to open wide the points of entry to new ther-
apeutic agents both within and outside of clinical trials. They
demanded that the paternalistic ethical warrant for the protection of
the vulnerable from research be replaced by an ethical regime
informed by respect for the autonomous choice of potential subjects
who could weigh, for themselves, the potential risks and benefits of
new treatments for HIV infection. Moreover, the revisionists
demanded a basic reconceptualization of the relationship between
researcher and subject. In place of protocols imposed from above, they
proposed a more egalitarian and democratic model in which negotia-
tion would replace scientific authority.
In the end, the shattering of the consensus that had governed
human subjects protection in the United States made problematical
what had been a bedrock assumption: that carefully controlled trials
were necessary to protect the vulnerable from the wide scale use of
drugs whose efficacy and safety had not been proven. In the intense
struggles that had fostered this radical reconceptualization, an unusual
alliance had emerged. Libertarians, antagonistic to the regulatory state
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and partisans of the “Reagan Revolution,” had joined with gay men
and advocates of disenfranchised women to oppose the architects of a
protective regime who had sought to protect the vulnerable from
undue risk.
As antagonists confronted each other, they predicted very different
consequences of the changes that were occurring, changes that had
implications far beyond the case of AIDS. Martin Delaney, of the AIDS
activist organization Project Inform, stated:
Regulatory practices contribute to the failure of science, demean the
public good and tread heavily on our civil liberties. . . . Science and
patients alike would be better served by a system that permits life threat-
ened patients some form of access to the most promising experimental
therapies, peacefully coexisting alongside a program of unencumbered
clinical research.
Giving voice to those who saw in the liberalized regime not only the
prospect for harming the desperate but a threat to the scientific enter-
prise upon which the future well-being of those infected with HIV
depended was researcher-physician Jerome Groopman. He contended
that “If the philosophy is that anyone can decide at any point what
drug he or she wants to take then you will not be able to do a clinical
trial.”
Just as the protective regime surrounding research in the United
States was a product of a history of abuse, efforts to enunciate ethical
standards for the conduct of research in Third World nations was
shaped by a history of exploitation, a history characterized by investi-
gations of the poor, designed to serve the interests of the privileged.
Central to those efforts was the belief that the ethical principles first
encountered in industrialized nations, shaped by the liberal tradition,
had a direct bearing on the norms that should govern research in very
different settings. Such universalism took as a given that insights
regarding cultural differences not serve as the basis for moral rela-
tivism.
Just as individual informed consent was the first principle of the
ethics of research in advanced industrial nations, it was at the heart of
the codes designed to guide research in the poorest nations. To pre-
clude exploitation, international consensus also existed on the extent to
which it was critical that research be responsive to the health needs
and priorities of the community in which it was to be carried out. What
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would remain a matter of uncertainty, however, was whether the
needs of the poorest and the requirement of responsiveness could jus-
tify research that would be unacceptable in the richest nations, e.g.,
whether the principle of universalism could accommodate research in
Burundi that would be prohibited in Brooklyn.
This is the issue that animated a furious international debate, when
a therapeutic intervention, after many years of disappointing failures,
was to prove remarkably effective in countering the transmission of
HIV during pregnancy. Although superficially a conflict over a techni-
cal matter involving research design — the role of placebos — the dis-
pute touched on the deepest questions of what ethical conduct means
in a world characterized by great inequalities and profound inequities.
In 1997, an editorial appeared in the New England Journal of Medicine
denouncing an international trial designed to determine if it was possi-
ble to develop an inexpensive clinical intervention that could provide
something approaching what had been attained in wealthy nations in
reducing the risk of mother-to-child HIV transmission. Those trials
assumed that even if successful, the more affordable interventions
would be less effective than was standard in Europe and America.
The standard of care in the United States and other advanced indus-
trial nations to prevent maternal-fetal transmission of HIV entailed a
great irony. The per-patient cost of prophylactic treatment ($800 for the
drug AZT alone) was affordable only in industrialized nations where
such transmission, although tragic, represented a relatively limited
problem. In developing countries, however, where maternal-fetal
transmission represents an epidemiologically significant disaster —
approximately half a million babies a year — the costs of prophylactic
treatment (disregarding the absence of the infrastructure necessary for
intravenous treatment during delivery) put the AZT regimen out of
reach. For example, in Uganda, among the poorest of Third World
nations, the cost of the AZT component of the standard regimen repre-
sents 400 times the yearly per capita expenditure on health care.
It was, therefore, a matter of some urgency that trials begin to deter-
mine whether radically cheaper alternatives to the regimen used in
wealthy nations could achieve at least some measure of reduced
maternal-fetal HIV transmission. In June 1994, a special consultation of
the World Health Organization considered the challenge and called for
the launching of studies to achieve that goal. The consultation made
clear its conclusion that placebo-controlled trials (trials in which a
comparison is made between an inert substance and the potentially
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active agent) “offer the best option for obtaining rapid and scientifi-
cally valid results.”
There was no question that a placebo-controlled trial would have
been considered unethical in the United States or any other advanced
industrial nation. No trial that denied access to the effective standard,
or to an intervention thought to hold the promise of being at least as
effective as, if not more effective than, the prevailing standard of care,
would have satisfied the requirements of ethical review. The question
posed by the furious controversy that unfolded was whether it was
ethical to conduct such a trial in a poor country, where no preventive
intervention was available and where the standard regimen was out of
reach as a potential therapy. The New England Journal of Medicine gave
its answer unambiguously:
Only when there is no known effective treatment is it ethical to compare
a potential new treatment with a placebo. When effective treatment
exists, a placebo may not be used. Instead, subjects in the control group
of the study must receive the best known treatment.
Given this premise, the Journal rejected as irrelevant the fact that health
care available in most Third World countries provided nothing like
health care available in industrialized countries. Citing the Declaration
of Helsinki, the international code of research ethics adopted by the
World Medical Association in 1964, the editorial noted that control
groups had to be provided with the best current therapy, not simply
that which was available locally.
The shift in wording between “best” and “local” may be slight, but the
implications are profound. Acceptance of this ethical relativism could
result in widespread exploitation of vulnerable Third World populations
for research programs that could not be carried out in the sponsor coun-
try.
Then, with the obvious suggestion that racism was involved, the Jour-
nal compared the recent research undertakings with the infamous
Tuskegee syphilis study in which poor, African-American men were
studied for decades to learn the consequences of untreated venereal
disease, even after effective, inexpensive therapy became available.
Women in the Third World would not receive antiretroviral treatment
anyway, so the investigators are simply observing what would happen
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to the subjects’ infants if there were no study. And a placebo-controlled
study is the fastest, most efficient way to obtain unambiguous informa-
tion that will be of greatest value in the Third World.
Finally, the editorial suggested darkly that narrow financial inter-
ests might have decided the shape of the research. Clinical trials had
become big business and, as in any business, work had to be done effi-
ciently. The ethics of research, however, had to have a different logic,
one that was not driven by considerations of efficiency above all else.
To the extent that the logic of business had displaced the logic of
research ethics, we had “not come very far from Tuskegee after all.”
However sharp the tone of the editorial, it was constrained by the
venue of the august New England Journal of Medicine. Its author, Marcia
Angell, was even harsher when she denounced her antagonists in an
op-ed piece in the Wall Street Journal.
All the rationalizations boil down to asserting that the end justifies the
means — which it no more does in Africa than it did in Alabama. It is
easy to see the failings of the Tuskegee study from a safe distance of 25
years. But those so offended by the comparison of the African research
with Tuskegee have yet to show how these studies differ in their funda-
mental failure to protect the welfare of human subjects.
A formal public response to the challenge in the New England Journal
of Medicine appeared two weeks later, signed by David Satcher, Direc-
tor of the U.S. Centers for Disease Control and Prevention, and Harold
Varmus, Director of the National Institutes of Health. Locating the crit-
icized trials in the context of the profound poverty of many nations
where mother-to-child transmission was so critical an issue, Satcher
and Varmus made clear that placebo-controlled trials were dictated by
the urgency of the situation. Only placebo-controlled trials, they
argued, could provide “definitive,” “clear,” “firm” answers about
which interventions worked, thus allowing governments to make
“sound judgments about the appropriateness and financial feasibility
of providing the intervention.” The failure to employ a placebo would
have made it difficult to clearly determine whether the affordable but
less effective intervention was better than no intervention at all. In
short, they concluded that placebos were crucial to policymakers
required to make relatively costly decisions under conditions marked
by profound poverty and scarce public health resources.
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Thus was the issue joined. So critical were the stakes involved in the
controversy that they ultimately provoked an international effort to
reconsider ethical standards of research in the Third World. The World
Medical Association undertook a series of consultations on the revi-
sion of the Declaration of Helsinki; the Council for International Orga-
nizations of Medical Sciences (CIOMS) did so as well. Finally, within
the United States, which funded much of the international research
that had been subject to scrutiny, the National Bioethics Advisory
Committee took up the issue of studies in poor nations.
As the fury of the clash that occasioned the reconsideration would
have predicted, the process of “rethinking” was anything but deco-
rous. One account of the World Medical Association’s efforts described
three years of “wrangling,” another spoke of “the ethics wars” and of
“cynical maneuvering.” What made the encounters so intense and furi-
ous is that they pitted against each other those who all saw themselves
as deeply committed to the protection of the vulnerable. Some saw in
any effort to craft “flexible” standards that reflected the uniquely
pressing context of international poverty and inequality the treacher-
ous embrace of moral relativism. Their opponents, however, persisted
in arguing that a failure to consider the context of investigation was a
failure of moral understanding. Principles could be universal; their
application, however, could not be rigid.
It was against this backdrop, as the efforts were drawing to a close,
that historian David Rothman published “The Shame of Medical
Research” in The New York Review of Books. In his virtual j’accuse, Roth-
man, with a long and distinguished career of examining exploitation in
the context of medicine, charged the international research community
with violating the simple moral maxim, “Do unto others as we do unto
ourselves.” Rejecting the assertion that his human rights approach to
medical research would hobble efforts to meet the needs of the poor
and desperate, he asked rhetorically why the utilitarianism of those he
opposed should be restricted to Third World AIDS. “If the threat of a
disease is dire why not allow investigators more latitude wherever
they are? With people living in pockets of poverty in the United
States?”
The profoundly difficult issue of research in the context of global
poverty is best demonstrated by conclusions reached by the World
Medical Association, the CIOMS, and the National Bioethics Advisory
Committee. Despite the fact that each body understood the consider-
able attention that was focused on their efforts, and the importance of
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forging a common standard, consensus could not be attained. Only the
World Medical Association, in its revision of the Declaration of
Helsinki, adopted the position of those like Rothman who asserted that
once an effective therapy was found, it became the standard against
which all further interventions had to be measured. Regardless of the
cost of the intervention, placebo-controlled trials were no longer toler-
able. The still preliminary CIOMS recommendations, on the other
hand, concluded that there might be sound scientific and ethical rea-
sons to reject the “best current” method standard, if the failure to use a
placebo would make the results inapplicable in the host country where
the search for affordable alternatives was essential. That, too, was the
position adopted by the U.S. National Bioethics Advisory Committee.
In the end, then, the AIDS-inspired debate over research ethics did
not end in consensus. Rather, it opened wide the question of whether
ethical principles could serve as a universal standard in a world char-
acterized by gross inequality, or whether that very inequality made
adherence to universal standards morally imperative.
V. Markets, Morality, and Mortality: Securing Access to Care
If the conflict over the ethics of clinical trials was framed by the need to
find affordable treatment for AIDS, it was the price of those same phar-
maceuticals that became the occasion for a controversy with far
broader implications. As I have noted, beginning in 1995, a new
approach to treating AIDS and HIV infections in the advanced indus-
trial world, involving a new class of drugs known as protease
inhibitors, had transformed the AIDS epidemic. Multi-drug “cocktails”
had radically slowed the disease in those who were infected and had
dramatically changed the extent to which death defined AIDS. But the
new regimens were complex, requiring many doses during the course
of the day, sophisticated laboratory monitoring, and great skill in
administration. And the drugs were very costly.
In nations with comprehensive national health programs, where
health care was seen as a social good and access to care a social right,
these new therapies became part of the treatment that those with HIV
received. In the United States, which alone among advanced democra-
tic nations did not recognize a social right to health care, and where
millions were without health insurance, the advent of the era of effec-
tive antiretroviral therapy posed a challenge that was not new.
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In the early 1970s, when kidney dialysis became available, the polity
was compelled to address the question of whether access to lifesaving
medicine should be limited by the ability to pay. In that dramatic
instance, a determination was made to create a federal program that
would pay the full cost of care for those with kidney failure. That ges-
ture only served to highlight the extent to which medical care was
rationed by the market in the United States.
It was within a system characterized by gross inequality that policy-
makers, pressed by advocates for those with HIV, developed a federal
program, the Ryan White CARE Act, that sought to assure access to
treatment for those who had neither private health insurance nor Med-
icaid coverage. Access to care was dramatically broadened, although
the progress was marred by continued inequality, revealed in the
extent to which African Americans and the poor were less likely to
receive optimal treatment.
On an international plane, the prospect of effective antiretroviral
treatment would pose challenges vaster by many orders of magnitude.
What justification was there for a system of pricing that put the cost of
drugs beyond the reach of the desperate? Could markets ever respond
to need where effective demand was nil? Could the monopoly con-
firmed by patent rights be compatible with a response dictated by
claims of the dying? Was the treaty on intellectual property rights,
incorporated into the World Trade Organization’s international
regime, a barrier to survival in the context of the AIDS epidemic? What
moral obligation did the wealthiest nations have to the poorest to pro-
vide the resources necessary to purchase the new lifesaving agents and
build the medical infrastructure necessary for their appropriate admin-
istration? Was there any reason to believe that a global community that
permitted millions to die each year from treatable and preventable dis-
eases such as tuberculosis and malaria would respond differently in
the face of AIDS?
VI. Progress and Protest
The first international AIDS conference to occur in the wake of studies
demonstrating the power of protease inhibitors was held in Vancou-
ver, Canada, in 1996. It was seized by a euphoria that was all the more
striking given the utter despair that had characterized the prior inter-
national meeting, held in Berlin in 1994. When, in 1998, the conference
again assembled under the banner “Bridging the Gap,” there was an
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increasing sense that the gulf was vast and growing between the coun-
tries where the new therapies were affordable and those where they
were beyond reach.
AIDS activists ultimately seized on this issue — Life Over Profits —
and began an international campaign to confront the pharmaceutical
industry. What seemed like an utterly quixotic undertaking, however,
ultimately took on worldwide dimensions linking protesters in the
United States, France, and South Africa, institutional proponents of
global health such as the World Health Organization, and a sympa-
thetic public. Within less than three years, the pharmaceutical industry
was placed on the defensive, perceived as protecting narrow self-inter-
est when the lives of millions were at stake. Against the claims that
high prices were necessary to fuel the engine of research, and that
patent protections were crucial to spurring investments in drug inves-
tigations, those who sought to change the terms of the discourse
asserted that urgency demanded that the barriers to drug access tum-
ble. Mark Wainberg, a Canadian who had served as the president of
the International AIDS Society, thus said in 2001, “This is a war, and
when you are in a war as we are worldwide with HIV which will claim
more lives than any other infectious disease in history, the rules of the
game have got to change.”
The struggle against the pharmaceutical industry could not have
occurred at a less propitious moment. The 1994 Trade Related Aspects
of Intellectual Property Treaty (TRIPS) imposed exacting limits on
what nations could do in imposing restrictions on free trade and the
market. The World Trade Organization was founded in 1995 and
incorporated the TRIPS accord into its regime. To be sure, the intellec-
tual property accord included provisions for extraordinary action in
the face of emergency situations. Nations faced with public health
threats could engage in “parallel imports,” purchasing drugs at the
lowest possible price, even from generic manufacturers who disre-
garded patents, or issue compulsory licenses to firms that could manu-
facture a potential product to meet a need that the market could not
accommodate. But the hegemony of market ideology and the aggres-
sive defense of the interests of industry by the U.S. Trade Representa-
tive meant that the advocates for radical adjustments would face
formidable resistance.
The first encounters over drug prices actually occurred in the early
1990s, when therapeutic prospects for dealing with AIDS were very
limited. The World Health Organization initiated discussions with
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pharmaceutical manufacturers, with the hope that a certain flexibility
in pricing would be available for developing countries. The response
from the industry presaged what would become its stance over the
next years. Their task was to discover therapeutic agents. It was the
task of others to make them accessible. Indeed, a year after discussions
began, the industry, which argued that AIDS drugs were simply too
costly for poor nations, objected to language in a proposed draft state-
ment that included terms such as “responsible prices,” “commercially
favorable terms,” and “special prices.”
With the failure of those initial discussions, it would not be until
1997 that another effort would be made to address the issue of drug
prices. Then the Joint United Nations Program on AIDS (UNAIDS)
began the HIV Drug Access Initiative, in which three pharmaceutical
firms were to negotiate discounted prices with four nations. Two of the
countries were in Africa, Uganda and Cote D’Ivoire. It was the dismal
results of this effort that set the stage for mounting pressure by the
year 2000. An evaluation found that in Uganda some 800 individuals
were receiving drugs out of 930,000 who might benefit. The story in
Cote D’Ivoire was not much better. The impact was “tiny.”
Some indication of how outrage against the evolving situation, with
increasingly effective care the standard in the wealthy nations stand-
ing in stark contrast to the absence of care for many millions in Africa
and Asia, could begin to shape public discussion occurred in the
United States. As Al Gore began his effort to win the presidential nom-
ination of the Democratic Party he was confronted by protestors from
ACT-UP, furious because the United States had threatened sanctions
against South Africa, which had passed legislation that would have
permitted parallel imports and compulsory licensing of drugs. “Gore’s
Greed Kills,” “Blood Money,” “Medical Apartheid” screamed the
posters. It was such protest, and the potential impact on Gore’s cam-
paign, that led the Clinton administration to adjust its policies.
Those adjustments in prices that had occurred and those pilot pro-
grams that had been established seemed to pale in the face of what was
increasingly viewed as a catastrophic situation. In January 2000, the
French ambassador to the United Nations called for a meeting between
the pharmaceutical industry, representatives of the industrialized
nations, and the poor nations to address the issue of drug access. The
Director General of the World Health Organization noted pointedly
that “The drugs were in the North, the diseases were in the South.”
Macalester International Vol. 11
224
With pressure mounting, five major pharmaceutical firms took the
extraordinary step of announcing, in May 2000, that they were ready to
negotiate steep cuts of up to 80 percent in the price of AIDS drugs for
Africa and other poor regions. Hailed by many as a critical turning
point, others saw it as a way for the pharmaceutical firms to maintain
control over the issue of pricing while preserving their patent rights.
But despite such gestures on the part of the pharmaceutical indus-
try, the public climate had begun to reflect an increasing sense of moral
revulsion. An industry that had presented itself as serving the interest
of health was clearly on the defensive. The mood was reflected in the
press not only in editorial comments but in news stories as well. On
July 9, 2000, The New York Times published a story about the drug flu-
conozole, used to treat cryptococcal meningitis, an opportunistic infec-
tion of those with HIV disease. A Kenyan doctor who could not
prescribe the drug because of its price said, “They get no peace. With
the intense pressure on the brain some go blind. Most just go into a
coma and die and by then they are in such pain that it is really a bless-
ing.” The reporter then continued, “As soon as he diagnoses crypto-
coccal meningitis in a patient he says he dispenses advice he hates: If
they want to be buried in their ancestral village as most Kenyans do
they should board a bus. They have only two or three weeks to live
and the cost of refrigerated trucks ruins many families.” The doctor
then said, “Can you imagine, as a doctor, having this conversation
with your patient? I have it once a week.” Without editorial comment,
the “news” story had underscored a sense of moral outrage.
Responding to continuing criticism, drug companies argued that, at
most, the price of drugs was a small part of the problem. The issue,
they said, was the fundamental limits of the medical infrastructure of
poor nations and the inability of the poorest to pay for even heavily
discounted drugs. But such arguments, whatever their merits, carried
little weight as long as prices remained high or as long as the offer to
negotiate price reductions entailed protracted processes. In early 2001,
the British medical journal The Lancet thus wrote, “The time has come
for the pharmaceutical industry and the governments who represent
them in trade disputes to acknowledge that the world is facing an
extraordinary challenge.”
Then, in February, an Indian generic pharmaceutical firm, Cipla,
changed the terrain. It announced that it had reached an agreement
with Doctors Without Borders to make a triple drug “cocktail” avail-
able for $350 a year per patient. It would sell such regimens to govern-
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ments for $600, $400 below the painstakingly negotiated price that
Senegal had been able to obtain from the pharmaceutical companies.
“This is,” said the chairman of Cipla, “a way to break the stranglehold
of multinationals.” The firms that sought fiercely to protect their
patent claims were outraged, describing Cipla and others that violated
patent rights as “pirates.”
Despite the furious response, Cipla’s announcement produced a
cascade of events. Merck cut the cost of one anti-AIDS drug by 92 per-
cent. Bristol-Myers Squibb announced that it would sell its two AIDS
medications below cost and would not oppose South Africa’s efforts to
bypass patents through compulsory licensing or parallel imports. In
words that could not have been imagined a few months earlier, the
company declared, “This is not about profits and patents, it is about
poverty and a devastating disease. We seek no profits in AIDS drugs in
Africa and we will not let our patents be an obstacle.” When Abbott
Laboratories followed suit, it declared, “AIDS has taken an unprece-
dented toll on the health, economic and social structure of Africa.
Abbott has taken this action to give people most affected by this dis-
ease a better opportunity to access care.” Finally, under threat from the
government of Brazil to issue a compulsory license for two drugs,
Merck agreed to slash the price of its products. Thus did the pressure
of the market produce a series of events that moral suasion had failed
to achieve over years of efforts.
In April 2001, a long-planned discussion was held, sponsored by the
World Trade Organization and the World Health Organization.
Despite fierce disagreements between AIDS activists and the pharma-
ceutical industry, and between the generic firms and the large pharma-
ceutical companies, broad agreement was reached on the importance
of differential pricing designed to adjust the cost of drugs to reflect the
purchasing capacity of poorer nations. The notion of “equity pricing”
that had not so long ago been anathema had assumed the status of a
common ground. It was within this context that yet another dramatic
event occurred. On April 19, the 39 drug companies that had brought
suit against the government of South Africa because of its legislation
that would have permitted the circumvention of patent restrictions
withdrew their case. “We don’t exist in a vacuum,” said the Chief
Executive Officer of GlaxoSmithKline. “We’re not insensitive to public
opinion, that is a factor in our decisionmaking.”
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VII. From Prices to Access
As drug prices began to fall, it became ever more apparent that the
challenges posed by the international pharmaceutical industry as it
resisted pressure by activists, generic manufacturers, and international
public opinion, were not without foundation. Even if drugs were pro-
vided at cost, even if the principle of equity pricing guided sales, even
if nations pursued the option of compulsory licensing and parallel
imports, the cost of providing antiretroviral therapy was simply
beyond the reach of the poorest and most HIV-burdened nations. And
even if drugs could be paid for, the necessity of a medical infrastruc-
ture (that could offer and monitor the use of drugs in a way that was
attentive to the needs of individual patients and to the risks to public
health from drug resistance) would require huge investments. This
was the context within which a remarkable movement to create a mas-
sive funding effort to respond to the threat of AIDS took shape. And
while the effort demonstrated how wildly optimistic The New York
Times was when it declared in a front page story, “Suddenly, the ques-
tion is no longer whether Africans will get life-saving drug cocktails,
but how,” it also made clear how, in the face of impending catastro-
phe, it was possible to give credibility to ideas that under normal cir-
cumstances would have been viewed as nearly utopian.
In early 2001, U.N. Secretary-General (and Macalester College grad-
uate) Kofi Annan issued a report in anticipation of a June General
Assembly meeting devoted to the AIDS epidemic, which he described
as “the most formidable development challenge of our time.” But his
call was conventional in its commitment to vaccine development and
prevention efforts. With that emphasis, it continued to reflect a broadly
shared view that treatment with the antiretroviral therapeutics avail-
able in the developed world could play a very limited role in resource-
constrained nations. Annan’s case mirrored a proposal from Jeffrey
Sachs, a Harvard development economist who had, more than a year
earlier, argued for a Millennium Vaccine Fund that would guarantee a
market for pharmaceutical firms that developed malaria, tuberculosis,
and AIDS vaccines. Such a fund would, he asserted, require a funda-
mental shift on the part of the world’s powerful economies. “We need
a serious discussion about long term finance for the international pub-
lic goods necessary for the Highly Indebted Poor Countries to break
through to prosperity. The rich countries are willing to talk about
every aspect except money. . . . ”
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By 2001, Sachs had taken on the challenge of AIDS in the poorest
nations directly. In so doing, he embraced the vision of those who had
asserted that it was morally unacceptable to stand by as millions of
men, women, and children faced certain death. He said, “To me it’s as
though the Black Death were going on in Europe in the 14th century
and China was sitting on a cure and saying, ‘Why should we help?’ We
would consider it the crime of the Millennium, if that had happened,
and yet we seem to be able to accommodate this without much trou-
ble.” Together with more than one hundred other Harvard faculty
members, he rejected the claim that only prevention efforts were
affordable for the poor. In an era of effective antiretroviral therapy,
access to care was imperative.
We believe that on moral, health, social and economic grounds the inter-
national community should provide new scientific and financial leader-
ship for a rapid scaling up of AIDS treatment in the poorest and hardest
hit countries of the world.
The goal was to treat one million patients in Africa within three
years. It was, according to Sachs and his colleagues, simply untrue that
the infrastructural capacity of African health care systems precluded
the provision of treatment. That there were limits was true, but they
could be overcome with appropriate international assistance.
To those who had asserted that efforts to provide treatment would
subvert already fragile prevention programs — a claim made by many
of the humanitarian foundations that had funded such efforts — Sachs
and his colleagues responded directly:
Treatment is necessary to optimize prevention efforts. When treatment is
not available less incentive exists for an individual to take an HIV test
since HIV positive status not only is associated with social stigmatiza-
tion but is tantamount to a death sentence. Ultimately, treatment of
infected individuals may become a major tool in AIDS prevention.
Finally, Sachs and his colleagues claimed that the provision of treat-
ment was necessary to preserve the social fabric of societies affected
with high levels of infection. “If the current lack of treatment continues
a demographic shift is predicted. . . such that teenagers will outnumber
their elders by 2020. Further, without treatment, millions of adults in
the prime of their working lives will die of AIDS and with them skills
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and knowledge that are necessary for human and economic develop-
ment.”
In assessing the potential costs of such an effort, the Harvard group
calculated that one million Africans could be treated for $1.1 billion
dollars a year. Were the program to expand to three million individu-
als—a goal achievable in five years—the cost would rise to $3.3 billion
a year. But even so vast an effort would not cover large numbers of
people in need of care. To reach those millions could require signifi-
cant investments in medical infrastructure that Sachs and his col-
leagues chose not to calculate. Finally, in addition to the costs of care, it
was estimated that for prevention efforts for Africa alone, $3 billion
was needed annually. Thus, in all, the first year’s effort in Africa
would require $4 billion.
To meet this vast commitment it was proposed that an HIV/AIDS
Prevention and Treatment Trust Fund be created. The sum involved,
while very large, was not beyond the capacity of the wealthiest
nations, totaling .01 percent of an aggregate GNP of $23 trillion.
The Harvard call had an electrifying effect, most clearly demon-
strated at a Rockefeller Foundation-sponsored meeting in Uganda in
mid-April, 2001. Addressing the final session of the meeting, the foun-
dation’s executive vice president declared that, “For the first time in
this two-decade old epidemic, AIDS care appears not only feasible but
also inevitable.” The North-South gap was described as “unpardon-
able,” since AIDS care was a “basic human right.”
Less than two weeks later, United Nations Secretary-General Kofi
Annan appeared before the African Summit on HIV/AIDS, Tuberculo-
sis and Other Infectious Diseases. He called for the creation of a global
trust fund that would spend $7 – 10 billion a year over “an extended
period” to combat the threat to the world’s poorest people. Most strik-
ing was his assertion that the care, which had for so long eluded men,
women, and children in the less developed nations, was a matter of
rights. Speaking to Africa’s lenders he said:
Even a year ago few people thought that effective treatment could be
brought within reach of poor people in developing countries. . . . There
has been a worldwide revolt of public opinion. People no longer accept
that the sick are dying simply because they are poor. Everyone who is
infected should have access to medicine and medical care. Now we
know that that is possible, it is surely an ethical imperative.
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Like the Harvard group and the Rockefeller Foundation, Annan
rejected claims that resources spent on care would imperil efforts at
prevention: “We cannot and should not chose between prevention and
treatment, we must do both.”
Strikingly, the idea of a global trust fund not only won the support
of editorialists identified with a liberal or social democratic posture,
but by powerful institutions as well. Within days of Annan’s speech,
the Group of Seven, the International Monetary Fund, and the govern-
ing committee of the World Bank endorsed the fund, in principle. The
Gates Foundation pledged $100 million to the effort. Not unexpect-
edly, the Final Declaration of the June United Nations Special General
Assembly session on AIDS asserted that $7 – 10 billion should be in
place by the year 2005. But between dramatic proposals based on
moral principles of solidarity with the most vulnerable and willing-
ness to provide the resources necessary to give life to such principles
and commitments there is a vast distance. When the G-8 met in Genoa
in July 2001, they committed $1.2 billion to the global fund that Annan
had called for. Declaring the gesture “laudable,” the U.N. Secretary-
General was quick to add, “It is not enough.”
As the international community began to articulate a consensus
regarding the need to rupture the economic barriers to antiretroviral
therapy, cautionary voices were to be heard. But remarkably, these
concerns centered on the need to do more, not less. In an editorial
applauding efforts at creating a global trust fund, The Lancet noted that
the successful provision of care to multitudes of those with HIV would
require a different kind of commitment:
Far more crucial are the elements of a sustainable primary health care
system. . . . Such fundamental services are not an eye-catching platform
for politicians and policymakers. Yet they are desperately needed — for
without them any effort to distribute medicines will fail. Such sums
should be at the center of a strategy to combat AIDS and other diseases.
The gulf between conviction and action has become all the more
stark as prevailing and pervasive international inequality has taken on
moral significance. What was the unfortunate has become unfair;
inequality has become inequity. In that translation, the possibility of
human agency, of political action to effect change, has opened wide. It
is far from certain how that opportunity will be apprehended.
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VIII. Envoi
At the conclusion of Plagues and People, William McNeill’s magisterial
history of epidemics and their impact on history, the enduring threat
of biology is underscored:
Ingenuity, knowledge and organization alter but cannot cancel human-
ity’s vulnerability to invasion by parasitic forms of life. Infectious dis-
ease, which antedates the emergence of humankind, will last as long as
humanity itself, and will surely remain as it has been hitherto one of the
fundamental parameters and determinants of human history.1
The AIDS epidemic has showed us with painful clarity how prescient
McNeill’s observation was. Never again will we have the security that
hubris had provided in the era before HIV. But we have also learned
another set of lessons. The course a pathogen takes is shaped by the
social environment it seeks to invade. Epidemics are therefore both
biological and social occurrences. While we may not be able to prevent
the emergence of new biological threats, we do have it within our
power to limit the points of social vulnerability. Whether we do so will
be a reflection of the extent to which we are committed to limiting
human suffering. How broadly we extend our commitments —
whether we hold them close or are global in our efforts — will reveal
the contours of our moral universe.
Secondly, we have learned the lesson again that scientific progress
does not end or limit the necessity of confronting moral questions. The
very opposite is the case. When nothing can be done to cure or treat the
sick, the options we have are limited. It is only when we are empow-
ered by scientific progress that we can answer the question: Who shall
live? In responding to that question we again confront the extent to
which our moral worldview is narrow or global.
From the depths of suffering imposed on us by the AIDS epidemic,
we have had to confront these profound questions. How we answer
them will be our legacy. And it will be the basis on which we will be
judged by history. 
Notes
1. William McNeill, Plagues and Peoples (New York: Anchor Press, 1976), p. 291.
Ronald Bayer
231
Further Reading
AIDS:
Bayer, Ronald. Private Acts, Social Consequences: AIDS and the Politics of Public Health.
New Brunswick: Rutgers University Press, 1989.
Bayer, Ronald, and Gerald Oppenheimer. AIDS Doctors: Voices from the Epidemic. New
York: Oxford University Press, 2000.
Kirp, David, and Ronald Bayer, eds. AIDS in the Industrialized Democracies. New
Brunswick: Rutgers University Press, 1992.
Epstein, Stephen. Impure Science: AIDS, Activism and the Politics of Knowledge. Berkeley:
University of California Press, 1996.
Human Experimentation:
Brody, Baruch. The Ethics of Biomedical Research: An International Perspective. New York:
Oxford University Press, 1998.
Council for International Organizations of Medical Sciences. International Ethical Guide-
lines for Biomedical Research Involving Human Subjects. Geneva, 1993.
Levine, Robert J. Ethics and Regulation of Clinical Research, 2nd ed. New Haven: Yale Uni-
versity Press, 1988.
National Commission for the Protection of Human Subjects. The Belmont Report: Ethical
Principles and Guidelines for the Protection of Human Subjects. Washington, D.C.: U.S. Gov-
ernment Printing Office, 1979.
Rothman, David. Strangers at the Bedside: A History of How Law and Bioethics Transformed
Medical Decisionmaking. New York: Basic Books, 1991.
Human Rights and Public Health:
Gostin, Lawrence, and Zita Lazzarini. Human Rights and Public Health in the AIDS Epi-
demic. New York: Oxford University Press, 1997.
Health and Human Rights: An International Journal.
Office of the United Nations High Commissioner for Human Rights and the Joint United
Nations Programs on HIV/AIDS. HIV/AIDS and Human Rights: International Guidelines.
Geneva, 1998.
Mann, Jonathan, Sofia Gruskin, Michael Grodin, and George Annas, eds. Health and
Human Rights: A Reader. New York: Routledge, 1999.
Macalester International Vol. 11
232
